title: Acne RA-1,2, a novel UV-selective face cream for patients with acne: Efficacy and tolerability results of a randomized, placebo-controlled clinical study.
abstract: BACKGROUND
  General skincare measures such as the use of moisturisers and products containing adequate photoprotection are important components of acne patients' management to complement the pharmacological regimen. Acne RA-1,2 is a novel dermato-cosmetic product which contains selective photofilters and active ingredients against the multifactorial pathophysiology of acne.
  
  
  OBJECTIVE
  To evaluate the tolerability of Acne RA-1,2 and its effect on the clinical signs of acne.
  
  
  METHODS
  This double-blind, placebo-controlled study randomized 40 adult patients with 10-25 comedones per half face to once-daily application of Acne RA-1,2 or placebo for 8 weeks. Evaluations after 4 and 8 weeks included the number of comedones, transepidermal water loss (TEWL), sebum production, and tolerability.
  
  
  RESULTS
  In the Acne RA-1,2 group, there was a significant 35% decrease in the mean number of comedones from 26 at baseline to 17 at Week 8 (P<.001), a 7% significant reduction in TEWL (9.32 to 8.66 g/h/m2; P<.001), and a 24% significant reduction in sebum production (154.8 to 117.6 μg/cm2; P<.001). The reductions in TEWL and sebum production were significantly greater than those in the placebo group at Weeks 4 and 8 (P<0.05). There were no adverse events.
  
  
  CONCLUSIONS
  Acne RA-1,2 was well tolerated and effective at reducing comedones and sebum production and improving epidermal barrier function. These results suggest that Acne RA-1,2 is useful against acne-prone facial skin, particularly as it targets sebum production, which topical pharmacological acne therapies do not address.
authors.affiliation: Farcoderm s.r.l., San Martino Siccomario, Italy.
authors.forename: Enza
authors.initials: E
authors.lastname: Cestone
authors.affiliation: Farcoderm s.r.l., San Martino Siccomario, Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Michelotti
authors.affiliation: Farcoderm s.r.l., San Martino Siccomario, Italy.
authors.forename: Valentina
authors.initials: V
authors.lastname: Zanoletti
authors.affiliation: Meda Pharma (a Mylan company), Monza, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Zanardi
authors.affiliation: Meda Pharma (a Mylan company), Monza, Italy.
authors.forename: Raffaella
authors.initials: R
authors.lastname: Mantegazza
authors.affiliation: Department of Biology and Biotechnology, University of Pavia, Pavia, Italy.
authors.forename: Maurizia
authors.initials: M
authors.lastname: Dossena
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D002164:Camphor / Q000008:administration & dosage* / Q000009:adverse effects; D002934:Cinnamates / Q000008:administration & dosage* / Q000009:adverse effects; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005145:Face; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D063465:Skin Cream; D016896:Treatment Outcome; D014466:Ultraviolet Rays; D055815:Young Adult
chemical_list: C000626399:Acne RA-1,2; D002934:Cinnamates; D003879:Dermatologic Agents; D002164:Camphor
keywords: acne; comedones; dermato-cosmetic; sebum; tolerability